Goldman Sachs Raises PT on Abbvie (ABBV) to $52
Goldman Sachs today maintained a Buy rating on Abbvie (NYSE: ABBV) and raised its price target to $52.00 (from $45.00) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)